Back to search

Article

Early  radiologic  response  after  two  cycles  of  neoadjuvant   chemoimmunotherapy  and pathologic  outcomes  in  resectable  non-small  cell  lung  cancer: A multicenter retrospective study

2026-08-19

Abstract excerpt

<title>Abstract</title> <p>Background Pivotal trials of neoadjuvant or perioperative chemoimmunotherapy for resectable NSCLC generally used 3–4 cycles, but whether response after 2 cycles can identify patients with deep pathologic regression remains unclear. Methods This multicenter retrospective cohort included 330 patients with resectable stage I-IIIC NSCLC treated with platinum-based chemotherapy plus a PD-1...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
2df3991f-635d-55c5-a7f8-2dafa055169e
DOI
10.21203/rs.3.rs-10615776/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Early radiologic response after two cycles of neoadjuvant chemoimmunotherapy and pathologic outcomes in resectable non-small cell lung cancer: A multicenter retrospective studyDOI 10.21203/rs.3.rs-10615776/v1
The Adjuvant-Phase Dilemma After Neoadjuvant Chemoimmunotherapy in Resectable NSCLC: Evidence and Response-Guided StrategiesSemantic proximity
Real-World Outcomes and Clinical Heterogeneity of First-Line Immunochemotherapy in Extensive-Stage Small-Cell Lung CancerSemantic proximity
Comparative Analysis of Clinical Outcomes Between Neoadjuvant Chemoimmunotherapy and Neoadjuvant Chemoradiotherapy in Patients with Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter, Retrospective StudySemantic proximity
Characteristics and Hematological Indicators Predictors of Immunotherapy Response in Advanced Non-Small Cell Lung CancerSemantic proximity
Neoadjuvant Combination Immunotherapy for Colorectal Cancer: Clinical and Molecular Predictors of Pathological Complete Response and Safety AssessmentSemantic proximity
[Potential Value of Neoadjuvant Immunochemotherapy in Patients with Driver Gene-positive Non-small Cell Lung Cancer].Semantic proximity
Real-world survival outcomes to first-line chemoimmunotherapy and biomarker analysis in extensive-stage small-cell lung cancerSemantic proximity
Effects of perioperative treatment of resectable adenocarcinoma of esophagogastric junction by immunotherapy (Adebrelimab) combined with chemotherapy (XELOX): protocol for a single-center, open-labeled study (AEGIS trial, neoadjuvant immunochemotherapy)Semantic proximity
Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer.Semantic proximity
Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of responseSemantic proximity
Tumor immune dynamics and long-term clinical outcome of stage IIIA NSCLC patients treated with neoadjuvant chemoimmunotherapySemantic proximity
Subgroup-Level Network Meta-Analysis for the Efficacy of First-Line Immunotherapy-Based Treatments in Advanced Non-Small Cell Lung CancerSemantic proximity
Select a neighboring publication to make it the new centre.